Navigation Links
NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
Date:1/12/2009

gh eight, compared with patients who received the control patch. Reduction in pain during Weeks two through twelve was also significantly greater in patients treated with Qutenza. Qutenza was generally well tolerated. The most common adverse effects were related to local, application site reactions and treatment-associated pain.

Anthony DiTonno, President and CEO, commented, "Current PHN treatment options have limitations that we believe present an opportunity for Qutenza to address. In addition to the potential for a long duration of effect, Qutenza acts locally, at the pain site, as opposed to through the central nervous system, and has the potential to manage pain resulting from PHN without causing some of the common side effects associated with currently available systemic treatment options. With both our NDA and MAA currently under review, we look forward to regulatory decisions on these applications and the potential for subsequent commercial launches of Qutenza in both the United States and European Union."

The first author of the publication, Miroslav Backonja M.D., Professor of Neurology, Anesthesiology and Rehabilitation Medicine at the University of Wisconsin School of Medicine, stated, "The results from the Phase 3 C116 study of Qutenza in patients with PHN showed that a single 60-minute application of Qutenza has the potential to provide targeted pain management for up to 12 weeks. I am very glad that Qutenza has the potential upon approval to offer our patients a significant improvement to the current treatment options for PHN."

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
2. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
3. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
4. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
5. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
10. ProUroCare Medical Inc. Announces Pricing of Equity Offering
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... The scientific team of a new biotech company ... academics in the field of aging Prof. Robert J. ... for model animals - 10 fold for nematodes) has recently ... primarily, around the stability and stress resistance of certain gene ... analysis of a model gene network links aging, stress resistance, ...
(Date:8/28/2015)... LOS ANGELES , FARUM, Denmark ... -- On July 31, 2015 the US Food ... for the treatment of Major Depressive Disorder in adult patients ... medication in the current episode. TMS is a non-invasive technique ... implicated in patients suffering from Major Depressive Disorder. The procedure ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de ... PHIA) anunció hoy su participación en el  Congreso ... sus soluciones cardiológicas más recientes y novedosas, entre ... que conectan a las personas y la tecnología ... ayudar a diagnosticar, guiar los tratamientos y permitir ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... 29, 2011 UBM Canon,s leading brand, Japan Medical Design ... the launch of its new Japanese-language website with enhanced content and ... website allows users to find the resources and information they ... Editor-in-Chief, EMDT , JMDMT , and CMDM ...
... June 29, 2011 Cayenne Medical, Inc., a private ... II Meniscal Repair System, its second generation device for ... on display at the 2011 American Orthopaedic Society for ... CA.   Tal David, MD, orthopedic sports ...
Cached Medicine Technology:UBM Canon Announces New Japanese-Language Website for Japan Medical Design & Manufacturing Technology: www.jmdmt.com 2Cayenne Medical, Inc. Launches CrossFix® II Meniscal Repair System 2
(Date:8/30/2015)... ... August 30, 2015 , ... Lizzie’s Lice Pickers , a company ... The company is currently offering lice head checks for just $10, which is a ... a 10% discount on their lice treatment products. “With kids returning to school, it ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... Jeff Fernandez will lead the expansion of global cosmeceutical and skin care brands. ... experience having spent the last 25 years working in operations, purchasing and management ...
(Date:8/29/2015)... ... 30, 2015 , ... Electronic Informed Consent for Clinical Trials:, ... EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about electronic informed consent is ... Clinical trial sites can now use audio, video and interactivity to educate participants ...
(Date:8/29/2015)... Irvine, CA (PRWEB) , ... August 29, 2015 , ... ... on a mission. His mission is to increase acceptance of the chiropractic field ... pain medications that further debilitate them. Although Chiropractic was made available to the ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 ... ... successful results and include treating the localized area with stretching, soft tissue manipulation. ... a neutral pelvic position have shown through research to improve treatment outcomes. ...
Breaking Medicine News(10 mins):Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... environmental factors like sunlight and cigarette smoke have discovered how ... to tolerate the DNA damage that leads to cancer and ... protein called DNA polymerase eta (Pol eta) and accompanies it ... When Pol eta is not present, alternative error-prone polymerases ...
... CINCINNATI--Emergency medicine researchers with the University of Cincinnati (UC) ... but dangerous condition in the emergency room. Pulmonary ... which a blood clot, usually from the legs, travels ... artery. But the most common way of testing for ...
... be made from some of the same parts used ... a way to measure the growth and drug susceptibility ... microscope. The new biosensor promises to speed treatment ... Richard Smalley Distinguished University Professor of Chemistry, Physics and ...
... at The University of Nottingham have brought cancer cells back ... The discovery could form a powerful new technology platform for ... Breast cancer is diagnosed in about 1.4 million women ... from the disease. A common cause of cancer is when ...
... This release is available in French . ... Ph. D student in biology at Universit du Qubec ... and Adjunct Professor Elsy Edouard, UQAM, Department of Biological ... in research on B-cell acute lymphocytic leukemia, a disease that ...
... the last few years, researchers have used a type of ... help them map changes in blood flow in the brain ... way to analyze fMRI data, which could improve is reported ... Design . Scientists have known since the 1890s that ...
Cached Medicine News:Health News:Chaperone enzyme provides new target for cancer treatments 2Health News:'Selective strategy' recommended for CT scans in emergency departments 2Health News:See how they grow: Monitoring single bacteria without a microscope 2Health News:See how they grow: Monitoring single bacteria without a microscope 3Health News:Scientists bring cancer cells back under control 2Health News:Discovery of a gene associated with a leukemia mostly affecting children 2Health News:Functional boost for magnetic resonance imaging 2
Convenience, Protection, Comfort and Security -- FirstChoice pouches are your product of choice if you are looking for the convenience of a one-piece pouch that is either cut-to-fit or pre-cut to you...
Inquire...
Superior comfort and flexibility are achieved through the revolutionary air pocket technology in the dimpled, ultra-thin SoftFlex skin barrier along with a discreet pouch shape and size....
Inquire...
Medicine Products: